Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A Study in Long-term Effects)

Journal of Vascular Surgery

Volumn 47, Issue 2, 2008, Pages

  Hiatt, William R ^a   Money, Samuel R ^b   Brass, Eric P ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CILOSTAZOL; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; WARFARIN;

ADULT; AGED; ARTERY DISEASE; ARTERY OCCLUSION; ARTICLE; BLEEDING; BRONCHITIS; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CLAUDICATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FEMALE; FEMORAL BLOOD OCCLUSION; FOLLOW UP; HEADACHE; HEART ARREST; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; TREATMENT OUTCOME;

EID: 38649119141     PISSN: 07415214     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvs.2007.10.009     Document Type: Article

References (20)

1. Hooi J.D., Stoffers H.E., Kester A.D., van R.J., and Knottnerus J.A. Peripheral arterial occlusive disease: prognostic value of signs, symptoms, and the ankle-brachial pressure index. Med Decis Making 22 (2002) 99-107
2. Criqui M.H., Langer R.D., Fronek A., et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326 (1992) 381-386
3. Hiatt W.R. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344 (2001) 1608-1621
4. Regensteiner J.G., Ware Jr. J.E., McCarthy W.J., Zhang P., Forbes W.P., Heckman J., et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 50 (2002) 1939-1946
5. Chapman T.M., and Goa K.L. Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs 3 (2003) 117-138
6. Packer M., Carver J.R., Rodeheffer R.J., Ivanhoe R.J., DiBianco R., Zeldis S.M., et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325 (1991) 1468-1475
7. Pratt C.M. Analysis of the cilostazol safety database. Am J Cardiol 87 (2001) 28D-33D
8. Brass E.P., Lewis R.J., Lipicky R., Murphy J., and Hiatt W.R. Risk assessment in drug development for symptomatic indications: a framework for the prospective exclusion of unacceptable cardiovascular risk. Clin Pharmacol Ther 79 (2006) 165-172
9. Food and Drug Administration, Cardiovascular and Renal Drug Advisory Committee. 85th meeting, July 9, 1998. Transcript. www.fda.gov/ohrms/dockets/ac/98tctm.htm Accessed: Mar 22, 2005
10. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Safety Guidelines. http://www.ich.org/cache/compo/276-254-1.html Accessed Feb 24, 2007
11. Newman A.B., Shemanski L., Manolio T.A., Cushman M., Mittelmark M., Polak J.F., et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 19 (1999) 538-545
12. Beebe H.G., Dawson D.L., Cutler B.S., Herd J.A., Strandness Jr. D.E., Bortey E.B., et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 159 (1999) 2041-2050
13. Dawson D.L., Cutler B.S., Meissner M.H., and Strandness D.E.J. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 98 (1998) 678-686
14. Dawson D.L., Cutler B.S., Hiatt W.R., Hobson II R.W., Martin J.D., Bortey E.B., et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 109 (2000) 523-530
15. Money S.R., Herd J.A., Isaacsohn J.L., Davidson M., Cutler B., Heckman J., et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 27 (1998) 267-274
16. Hiatt W.R., Regensteiner J.G., Creager M.A., Hirsch A.T., Cooke J.P., Olin J.W., et al. Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication. Am J Med 110 (2001) 616-622
17. Brass E.P., Anthony R., Cobb F.R., Koda I., Jiao J., and Hiatt W.R. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol 48 (2006) 2539-2545
18. Brass E.P., and Hiatt W.R. Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies. Vasc Med 11 (2006) 141-145
19. Amsallem E., Kasparian C., Haddour G., Boissel J.P., and Nony P. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev (2005) CD002230
20. Wilhite D.B., Comerota A.J., Schmieder F.A., Throm R.C., Gaughan J.P., and Rao A.K. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 38 (2003) 710-713